Preview Mode Links will not work in preview mode

This Week in Cardiology

May 7, 2021

COVID-19 and BMI, TAVR vs SAVR, subcutaneous ICD, SGLT2 inhibitors, and physician-Moms are the topics John Mandrola, MD, discusses in this week’s podcast.


COVID-19 Severity Starts in Normal BMI Range, Especially in Young

- Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study


VARC-3 Sets Goalpost for Future Aortic Valve Trials

- Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research

TAVR Availability

Patchy Growth of TAVR Programs Leaves Poorer Communities Behind


Trade-offs Between Subcutaneous, Transvenous ICDs on Display in EFFORTLESS

- Implant and Midterm Outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry: The EFFORTLESS Study

- Reduction in Inappropriate Therapy and Mortality through ICD Programming

- Low inappropriate shock rates in patients with single- and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms: PainFree SST trial primary results

Dapagliflozin and CKD

FDA Approves Dapagliflozin (Farxiga) for Chronic Kidney Disease


New Physician Moms Need More Resources and Less Guilt in the Workplace

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact